Rna Diagnostics Inc. is a molecular diagnostics company developing diagnostic tools to assist in the management of cancer chemotherapy.

The company’s first product, RNA Disruption Assay™ (RDA™), is a novel test that helps oncologists to rapidly assess the effectiveness of cancer chemotherapy. RDA can determine whether chemotherapy is working effectively in the individual patient early in treatment thereby guiding clinical decision making.

Highlights include:

• The only diagnostic tool that predicts early in treatment how a patient will respond in chemotherapy
• Potential to radically improve cancer chemotherapy management
• RDA spares non-responders from harmful adverse effect of chemotherapy while improving clinical outcomes
• RDA provides significant cost savings for healthcare payers
• Proof of principle established in a major multi-centre breast cancer clinical trial
• Significant advantages over competing chemotherapy management technologies